Serum NGAL to Clinically Distinguish Cholangiocarcinoma from Benign Biliary Tract Diseases

Aim. To determine whether the serum level of NGAL can discriminate cholangiocarcinoma from benign biliary tract disease in patients. Methods. This study was performed according to a prospective-specimen-collection, retrospective-blinded-evaluation (PRoBE) design. A total of 50 cholangiocarcinoma and...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Prif Awduron: Leelawat, Kawin, Narong, Siriluck, Wannaprasert, Jerasak, Leelawat, Surang
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: SAGE-Hindawi Access to Research 2011
Pynciau:
Clinical Study
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC3170848/
https://ncbi.nlm.nih.gov/pubmed/21994874
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4061/2011/873548
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg